This Week in Cardiology

Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week’s podcast.

Mortality after AF ablation, cardiac rehab programs, hypertrophic cardiomyopathy, and clinician wellness are the topics Dr. John Mandrola discusses in this week’s podcast.

AF after TAVR, opioids after cardiac devices, hypertension in black adults, and post-cardiac surgery AF are the topics Dr John Mandrola discusses in this week’s podcast.

The Nobel Prize, more on the EXCEL trial, the costs of cardiac tests, familial hypercholesterolemia, and burnout are the topics discussed by Dr John Mandrola in this week’s podcast.

Left main PCI vs CABG trials and TAVR vs SAVR—in this week’s podcast, Dr John Mandrola takes a deeper dive.

Social effects of medicine, SGLT2 inhibitors, CIED infections, equity in cardiology, and post-PCI anti-thrombotic therapy are the topics discussed by Dr John Mandrola in this week’s podcast.

The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week’s podcast.

More from ESC: Antiplatelets and NOACs, blood glucose control, high sensitivity troponin tests, and ICD trials are all covered by John Mandrola, MD, in this week’s podcast.

Six major trials from the ESC meeting in Paris are reviewed by John Mandrola, MD, in this week’s podcast.

Digital health, a new LDL-c lowering drug, PCSK9i outcomes in higher risk patients, and an ESC preview are discussed by John Mandrola in this week’s podcast.